Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sedation Practices in Intensive Care Evaluation: SPICE III
2013-003307-20Phase 4Active
- Sponsor
- Australia and New Zealand Intensive Care Research Centre
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine in critical illness, acute respiratory decompensation and respiratory failure (2 arms), sponsored by Australia and New Zealand Intensive Care Research Centre. Primary endpoints: 90-day all-cause mortality and 180-day all-cause mortality. Started Oct 2013; status: active.
02
Drugs
dexmedetomidine
03
Conditions
critical illnessacute respiratory decompensationrespiratory failure
Beyond the preview
Go deeper on 2013-003307-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003307-20.